Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AstraZeneca
Femme et Homme Max 99 ans
AstraZeneca AB, AstraZeneca Sverige
MAJ Il y a 4 ans
A randomised, double blind, double dummy, multicentre phase III study comparing the efficacy of budesonide/formoterol (Symbicort® forte Turbuhaler®) and oral prednisolone + formoterol (Oxis® Turbuhaler) during two weeks, in COPD patients with an acute exacerbation, followed by twelve weeks open follow up period with budesonide/formoterol (Symbicort forte Turbuhaler) - SPACE
To assess if a double standard dose of Symbicort forte Turbuhaler during two weeks is as effective as an oral course of prednisolone + Oxis Turbuhaler (during two weeks) for the treatment of an acute ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
Multicentre, open label, extension study of treatment with gefitinib (IRESSA™) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatment
The primary objective of this study is to provide, or continue to provide, gefitinib treatment to patients who have recently participated in other gefitinib clinical studies.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
AstraZeneca Clinical Research Group (UK)
MAJ Il y a 5 ans
A Study to Compare the Effect of Two Blinded Doses of Casodex (ICI 176,334 100 mg and 150 mg daily) and Castration in the Treatment of Advanced Carcinoma of the Prostate
Not provided at time of registration
Pays
United Kingdom
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
An open-label, non-comparative trial to evaluate the safety, efficacy and pharmacokinetics of FASLODEX (fulvestrant) in girls with progressive precocious puberty associated with McCune-Albright Syndrome
The primary objective of the trial is composed of two components: A safety and efficacy component and a pharmacokinetics (PK) component. All patients fulfilling the eligibility criteria will particip...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
Assess Efficacy and Safety of AZD6244 in Combination with Docetaxel in Patients receiving second line NSCLC treatment
To assess the efficacy in terms of Progression-Free Survival (PFS) for each comparison of selumetinib in combination with docetaxel, compared to placebo in combination with docetaxel
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
104 Week Trial to Evaluate the Comparative Effectiveness of dapagliflozin and Standard of Care in Type 2 Diabetes. The DECIDE Study
To assess differences between dapagliflozin and SOC (subsequent to at least 3 months post-randomization) in the achievement of clinical success in the treatment of Type II diabetes mellitus using a 4-...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or Mildly Symptomatic
To determine the effect of ZD4054 on overall survival, defined as time to death (from randomisation) from any cause, compared to placebo
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
Evaluation of Ceftaroline Fosamil versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
To assess whether ceftaroline fosamil is noninferior to vancomycin plus aztreonam in the clinical cure rate at the test of cure visit in both the modified intent-to-treat and clinically evaluable anla...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
Prevention of cardiovascular events (eg, death from heart or vascular disease, heart attack, or stroke) in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin
The primary objective of the study is to see if a new drug called ticagrelor given twice daily in addition to the aspirin therapy decreases the frequency of cardiovascular events (e.g., death from hea...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A double-blind randomized placebo-controlled, parallel-group study during 12 weeks to investigate whether the drugs Epanova® and dapagliflozin can dimish the liver fat content in patients with diabetes type 2
To evaluate the efficacy of the combination therapy (Epanova® + dapagliflozin) when compared to placebo with respect to reduction in liver fat content (%) at the end of 12 weeks of double-blinded trea...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
15
16
17
18
19
20
21
22
23
24
Suivant